TITLE

Fresh from the pipeline: Gefitinib

AUTHOR(S)
Muhsin, Mohamed; Graham, Joanne; Kirkpatrick, Peter
PUB. DATE
July 2003
SOURCE
Nature Reviews Drug Discovery;Jul2003, Vol. 2 Issue 7, p515
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Gefitinib (Iressa; AstraZeneca) is the first in a new class of targeted anticancer drugs that inhibit the tyrosine kinase activity of the epidermal growth factor receptor. Following Japanese approval in 2002, gefitinib was approved by the US FDA in May 2003 for the treatment of advanced non-small-cell lung cancer after other treatment options have failed. Despite several setbacks during the development of gefitinib, might it now be back on the path to blockbuster status?
ACCESSION #
10068371

 

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics